The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma (ACADIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06307665
Recruitment Status : Recruiting
First Posted : March 13, 2024
Last Update Posted : May 23, 2024
Sponsor:
Collaborator:
Parexel
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.

Condition or disease Intervention/treatment Phase
Asthma Combination Product: BDA MDI Combination Product: AS MDI Phase 3

Detailed Description:

This is a randomized, double-blind, multicenter, parallel-group Phase IIIb study with a fixed treatment period of 52 weeks.

The study will consist of 3 periods:

  1. Screening period (7 to 28 days)
  2. Treatment period of 52 weeks
  3. Safety follow-up period (7 to 14 days after the end of treatment [EOT] visit)

Participants who meet the eligibility criteria will be randomly assigned to BDA MDI 160/180 micrograms (μg) or AS MDI 180 μg treatment groups in a 1:1 ratio on top of their own usual maintenance therapy during treatment period.

This study will also include a pharmacokinetic (PK) sub-study with single visit scheduled after the safety follow-up visit in the main study. During PK sub-study, single dose of open-label BDA MDI 160/180 μg will be administered.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 440 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Multicenter, Parallel Group, Phase IIIb 52 Week Study Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma (ACADIA)
Actual Study Start Date : May 20, 2024
Estimated Primary Completion Date : October 6, 2027
Estimated Study Completion Date : October 6, 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: Budesonide/albuterol metered -dose inhaler (BDA MDI)
Participants will receive BDA MDI 160/180 μg (given as 2 puffs of 80/90 μg) as needed.
Combination Product: BDA MDI
Participants will receive oral inhalation of BDA MDI 160/180 μg taken as 2 puffs of 80/90 μg as needed.
Other Name: PT027

Active Comparator: Albuterol sulfate metered-dose inhaler (AS MDI)
Participants will receive AS MDI 180 μg (given as 2 puffs of 90 μg) as needed.
Combination Product: AS MDI
Participants will receive oral inhalation of AS MDI 180 μg taken as 2 puffs of 90 μg as needed.
Other Name: PT007




Primary Outcome Measures :
  1. Annualized rate of severe asthma exacerbations (AAER) [ Time Frame: From Randomization (Day 1) to Week 52 (EOT) ]
    The effect of BDA MDI compared with AS MDI, both administered as needed, on the AAER in participants with asthma will be evaluated.


Secondary Outcome Measures :
  1. Time to first (TTF) severe asthma exacerbation [ Time Frame: From Randomization (Day 1) to Week 52 (EOT) ]
    The effect of BDA MDI compared with AS MDI, both administered as needed, on the risk of a first severe asthma exacerbation in participants with asthma will be evaluated.

  2. Annualized total systemic corticosteroids (SCS) exposure for treatment of asthma [ Time Frame: From Randomization (Day 1) to Week 52 (EOT) ]
    The effect of BDA MDI compared with AS MDI, both administered as needed, on the annualized total SCS exposure for treatment of asthma in participants with asthma will be evaluated.

  3. Number of participants with adverse events (AEs) and severe adverse events (SAEs) [ Time Frame: Up to Week 52 ]
    The safety and tolerability of BDA MDI compared with AS MDI in participants with asthma will be assessed.

  4. Maximum Observed Concentration (Cmax) [ Time Frame: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose ]
    The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized.

  5. Area under concentration-time curve from time 0 to last quantifiable concentration (AUClast) [ Time Frame: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose ]
    The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized.

  6. Area under concentration-time curve from time 0 to infinity (AUCinf) [ Time Frame: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose ]
    The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized.

  7. Time to reach maximum concentration following drug administration (Tmax) [ Time Frame: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose ]
    The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized.

  8. Time of last quantifiable concentration (Tlast) [ Time Frame: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose ]
    The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized.

  9. Terminal elimination half-life (t½λz) [ Time Frame: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose ]
    The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized.

  10. Terminal elimination rate constant (λz) [ Time Frame: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose ]
    The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized.

  11. Apparent total body clearance (CL/F) [ Time Frame: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose ]
    The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized.

  12. Apparent volume of distribution based on the terminal phase (Vz/F) [ Time Frame: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose ]
    The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Confirmed clinical diagnosis of asthma at least 12 months.
  • Receiving one of the following scheduled asthma maintenance therapies for at least 3 months with stable dosing for at least the last one month

    1. Low-to-high-dose Inhaled corticosteroid(s) (ICS)
    2. Low-to-high-dose ICS with or without long-acting β2-agonist (LABA) and one additional maintenance therapy from the following: leukotriene receptor antagonist (LTRA), long-acting muscarinic antagonist (LAMA), or theophylline
  • Receiving inhaled short-acting β2-agonist (SABA) as needed.
  • A documented history of at least one severe asthma exacerbation within 12 months.
  • Use of Sponsor-provided albuterol sulfate inhalation aerosol medication.
  • Demonstrate acceptable MDI administration technique as assessed by the investigator; use of spacers is prohibited.
  • Able to perform acceptable and reproducible peak expiratory flow (PEF) measurements as assessed by the investigator.
  • Participants must adhere to protocol specific contraception methods.
  • Negative urine pregnancy test for participants of childbearing potential.
  • Have a BMI < 40 kg/ m^2.
  • Capable of giving assent (signing the assent form) to participate in the study which includes compliance with the requirements and restrictions. The caregiver of the patient must be capable of giving written informed consent for the patient's participation in the study. Consent and assent forms must be completed prior to any study-specific procedures.

Exclusion Criteria:

  • Life-threatening asthma defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s).
  • Experienced > 3 severe asthma exacerbations within 12 months before screening.
  • Completed treatment for lower respiratory infection and severe asthma exacerbation with SCS within 4 weeks of screening.
  • Upper respiratory infection involving antibiotic treatment not resolved.
  • Current smokers, former smokers with > 10 pack-years history, or former smokers who stopped smoking < 6 months (including all forms of tobacco, e-cigarettes [vaping], and marijuana).
  • Other significant lung disease, including regular or occasional use of oxygen.
  • Historical or current evidence of a clinically significant disease including, but not limited to: cardiovascular, hepatic, renal, hematological, neuropsychological, endocrine, or gastrointestinal disorders.
  • Cancer not in complete remission for at least 5 years.
  • History or hospitalization for psychiatric disorder or attempted suicide within one year.
  • Significant abuse of alcohol or drugs, in the opinion of the investigator.
  • Oral corticosteroid(s) (OCS)/SCS use (any dose and any indication) within 4 weeks before Visit 1 or chronic use of OCS/SCS (≥ 3 weeks use in 3 months prior to Visit 1).
  • Use of any oral SABAs within one month.
  • Having a known or suspected hypersensitivity to albuterol/salbutamol, or budesonide and/or their excipients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06307665


Contacts
Layout table for location contacts
Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com

Locations
Layout table for location information
United States, Florida
Research Site Not yet recruiting
Destin, Florida, United States, 32541
United States, Indiana
Research Site Not yet recruiting
Indianapolis, Indiana, United States, 46202
United States, Louisiana
Research Site Not yet recruiting
Lafayette, Louisiana, United States, 70508
United States, Maryland
Research Site Not yet recruiting
White Marsh, Maryland, United States, 21162
United States, Michigan
Research Site Not yet recruiting
Detroit, Michigan, United States, 48201
United States, Minnesota
Research Site Not yet recruiting
Mankato, Minnesota, United States, 56001
United States, New Jersey
Research Site Not yet recruiting
Newark, New Jersey, United States, 07103
Research Site Not yet recruiting
Ocean City, New Jersey, United States, 07712
United States, New Mexico
Research Site Not yet recruiting
Albuquerque, New Mexico, United States, 87106
United States, New York
Research Site Not yet recruiting
Cortland, New York, United States, 13045
Research Site Not yet recruiting
Hawthorne, New York, United States, 10532
Research Site Not yet recruiting
New York, New York, United States, 10032
Research Site Not yet recruiting
Vestal, New York, United States, 13850
Research Site Not yet recruiting
Watertown, New York, United States, 13601
United States, Ohio
Research Site Not yet recruiting
Cincinnati, Ohio, United States, 45229
United States, Oklahoma
Research Site Recruiting
Oklahoma City, Oklahoma, United States, 73120
United States, Pennsylvania
Research Site Not yet recruiting
Pittsburgh, Pennsylvania, United States, 15241
United States, South Dakota
Research Site Not yet recruiting
Sioux Falls, South Dakota, United States, 57105
United States, Texas
Research Site Not yet recruiting
Austin, Texas, United States, 78759
Research Site Not yet recruiting
Beaumont, Texas, United States, 77701
Research Site Not yet recruiting
Corsicana, Texas, United States, 75110
Research Site Not yet recruiting
Dallas, Texas, United States, 75231
Research Site Not yet recruiting
Houston, Texas, United States, 77065
Research Site Not yet recruiting
San Antonio, Texas, United States, 78229
United States, Washington
Research Site Not yet recruiting
Bellingham, Washington, United States, 98225
Sponsors and Collaborators
AstraZeneca
Parexel
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT06307665    
Other Study ID Numbers: D6934C00001
First Posted: March 13, 2024    Key Record Dates
Last Update Posted: May 23, 2024
Last Verified: May 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access Criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non negotiable contract for data accessors) must be in place before accessing requested information.
URL: https://vivli.org/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by AstraZeneca:
Fast-acting β2-agonist
Metered-Dose Inhaler (MDI)
Bronchodilatory
Inhaled corticosteroids
Anti-inflammatory
Rescue Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases